European PharmaNovo Nordisk Outsources Parkinson's Programs to AI Partner as Stock Surges 24.9%Salvado•Jun 9, 2026
European Pharmaceutical InnovationNovo Nordisk Licenses Parkinson's Therapy to AI Startup, Shares Rise 24.9% in 30 DaysSalvado•Jun 5, 2026
European PharmaNovo Nordisk's 24.9% Rally Backs AI Partnership Model Over In-House BiologySalvado•May 31, 2026
European PharmaNovo Nordisk Stock Surges 24.9% in 30 Days as AI Reshapes European Drug DiscoverySalvado•May 27, 2026
European Pharmaceutical InnovationNovo Nordisk Closes Cell Therapy Unit, Outsources Parkinson's to AI Partner as Stock Surges 25%Salvado•May 18, 2026
European PharmaNovo Nordisk Licenses Parkinson's Cell Therapy to AI Partner, Closes Internal UnitSalvado•May 16, 2026
European PharmaNovo Nordisk Stock Jumps 24.9% After Closing Cell Therapy Unit and Licensing Parkinson's Program to AI PartnerSalvado•May 13, 2026
